Investor FAQ

Yes, it can. In February 2024, Bioharvest announced that it had signed two contracts with industrial partners to produce plant based molecules, and that this would be done under the new Contract Development and Manufacturing Organization (CDMO) business unit. This new business unit allows pharmaceutical, cosmeceutical, nutraceutical and nutrition industry leaders the opportunity to partner with BioHarvest to utilize its Botanical Synthesis Process technology through a typical CDMO contracting model. This proprietary process technology enables the development and manufacturing of patentable plant based small molecules, complex molecules,  and unique compositions which include both small and complex molecules.

BioHarvest Sciences is a publicly listed company, listed in Canada on the Canadian Securities Exchange under the symbol “BHSC”.   

In the US, Bioharvest trades on the OTCQB Markets under the symbol “CNVCF”.  

In Europe, BioHarvest trades on the Deutsche Borse Frankfurt Exchange under the symbol “8MV”  

All shares purchased in any of these markets are for the same public shares of Bioharvest, all of which are issued via the Canadian Securities listing.  

As an early-stage biotechnology company, additional financings may be undertaken to fund expansion and development. These investment opportunities will be announced via news release.   

All investor-related questions are welcome, and we will respond within 24 hours. Contact our Investor Relations team at info@bioharvest.com.  

Botanical Synthesis is non-GMO. Our process enables us to elicit (increase concentrations of) molecules containing active plant ingredients that are produced by the plant cells. We identify the cells that are best able to produce the desired phytochemicals, and then those cells become the cell bank for future harvests. No genetic modification is involved.  

Yes, it can. In February 2024, Bioharvest announced that it had signed two contracts with industrial partners to produce plant based molecules, and that this would be done under the new Contract Development and Manufacturing Organization (CDMO) business unit. This new business unit allows pharmaceutical, cosmeceutical, nutraceutical and nutrition industry leaders the opportunity to partner with BioHarvest to utilize its Botanical Synthesis Process technology through a typical CDMO contracting model. This proprietary process technology enables the development and manufacturing of patentable plant based small molecules, complex molecules,  and unique compositions which include both small and complex molecules.

If you have any questions about our technology or commercialization plans, contact us at info@bioharvest.com. All investor-related queries will be answered within 24 hours.  

If you are an investor who would like to join an informal Q+A Zoom call with a small group of other investors and CEO Ilan Sobel, we host a Zoom “Coffee With Ilan” Q+A weekly, at 11am PST. Contact info@bioharvest.com to book your spot in an upcoming session.  

Subscribe to our social media channels for a steady stream of corporate information, or subscribe to our News Alert list to receive our biggest news updates directly from us.  

We strive to be as transparent and communicative as is possible for a public company. BioHarvest hosts interactive shareholder webinars quarterly, and we welcome all comments and questions from our shareholder partners as we push forward on our mission to improve human wellness while doing no harm to the world.  

Our technology platform is capable of growing any type of plant cells. We prioritize our products in order to optimize both Human Utility Value and shareholder return. To date, we have announced that our Research and Development has conducted extensive research on grape, olive, pomegranate, and cannabis cell banks. While our Research and Development team is actively reviewing other cell types, our current focus on near term profitability is to prioritize the development of products that include VINIA. The first “VINIA inside” product released in December 2023 was our Premium Medium roast and decaffeinated VINIA functional coffees. The future product development pipeline includes protein bars, a performance hydration product, and skin formulations.  Click here to view the December 13, 2023 news release outlining these future products.

Our clinical studies program is actively testing new pharmaceutical horizons for our Red Grape Cells unique compositions and these are expected to produce new options for future products.  

2022 global VINIA sales orders were $6.1Million USD, and Bioharvest is expecting final 2023 VINIA revenue to exceed $12Million USD. Increasing VINIA sales will be achieved through a combination of increasing production, and by executing on campaigns with wider reach. We are also working to expand demographic appeal, such as addressing younger consumers looking for healthy options to improve energy levels. In addition to the December 2023 launch of our first “VINIA inside” Hot Beverages, we will be releasing additional products in 2024, and we are working to expand into new markets. Click here to read the announcement of our license to sell VINIA into Canada.

Three key marketing initiatives for 2023 included the launch of a multi-tiered VINIA sales program that included TV, the introduction of a VINIA customer referral program, and development of a  partnership program that includes influencers, athletes, doctors, and affiliate networks.